Henatinib is an orally active small-molecule multi-kinase inhibitor with broad anti-tumor activity; it inhibits the activity of VEGFR-2, c-kit, and PDGFR with IC50 values of 0.6 nM, 3.3 nM, and 41.5 nM, respectively; it significantly suppresses VEGFR-2 phosphorylation and its downstream signaling pathways in human umbilical vein endothelial cells (HUVECs).